Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience

Christopher Jensen, Mazyar Shadman, Andres Chang et al. Nov 03, 2025 pp. 3885-3885 10.1182/blood-2025-3885

Abstract Background: Venetoclax (VEN)+obinutuzumab (VO) is an effective therapy for CLL/SLL requiring regular monitoring for tumor lysis synd...

Perturbation of iNKT differentiation during clonal hematopoiesis from rewiring of inflammation and lipid presentation

Francesca Luca, Alana Franceski, Paran Goel et al. Nov 03, 2025 pp. 978-978 10.1182/blood-2025-978

Abstract Invariant Natural Killer T (iNKT) cells are a rare, non-conventional T cell subset that recognize lipid antigens presented by the M...

Underexplored mutations in plasma cell myeloma

Kirti Arora, Diana Basali, Yasar Shad et al. Nov 03, 2025 pp. 4025-4025 10.1182/blood-2025-4025

Abstract Background: Mutation testing with Next Generation Sequencing (NGS) is routinely used for risk stratification at the time of diagnosi...

A target trial emulation to assess the comparative incidences of venous thromboembolism in patients with chemotherapy induced thrombocytopenia treated with romiplostim.

Divyash Shah, Cy R. Wilkins, Andriy Derkach et al. Nov 03, 2025 pp. 21-21 10.1182/blood-2025-21

Abstract Introduction Chemotherapy induced thrombocytopenia (CIT) commonly occurs in patients with solid tumors often resulting in dosage re...

Pembrolizumab + GVD with ctdna-guided consolidation for relapsed/refractory classic Hodgkin lymphoma: A multicenter phase 2 Study of the University of California hematologic malignancies consortium

Michael Randall, Wendy Swetzig Dhiman, Chiung-Yu Huang et al. Nov 03, 2025 pp. 3630-3630 10.1182/blood-2025-3630

Abstract The current standard of care for relapsed/refractory classic Hodgkin lymphoma (R/R cHL) is salvage chemotherapy followed by autolog...

Alpha-thalassemia and red blood cell heterogeneity in sickle cell trait: Interim findings from the achieving understanding of the natural history of sickle cell trait (AUNT) study

Rakhi Naik, Umut Gurkan, Mohan Madisetti et al. Nov 03, 2025 pp. 533-533 10.1182/blood-2025-533

Abstract Introduction: Heterozygous inheritance of hemoglobin S (HbAS) is known as sickle cell trait (SCT). While most individuals with SCT...

Real-world patient characteristics, treatment patterns, and outcomes in patients with myelodysplastic syndromes

Mike Yang, Shiyun Zhu, Kenneth Poon et al. Nov 03, 2025 pp. 7398-7398 10.1182/blood-2025-7398

Abstract Background: Due to its rarity and heterogeneity, management of myelodysplastic syndrome (MDS) can be challengin...

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

Yuqin Song, Qingqing Cai, Xiaoqiong Tang et al. Nov 03, 2025 pp. 886-886 10.1182/blood-2025-886

Abstract Introduction Patients with relapsed or refractory mantle cell lymphoma (r/r MCL) following prior covalent Bruton tyrosine kinase in...

Overcoming therapy resistance with multi-targeted CAR-T cells secreting bispecific antibody (BsAb) for the treatment of B-cell malignancies

Qing Yin, Jing Gao, Xiangao Huang et al. Nov 03, 2025 pp. 7263-7263 10.1182/blood-2025-7263

Abstract Adoptive T-cell immunotherapies have revolutionized the treatment landscape for aggressive B-cell malignancies. Despite high rates...

Impact of anti-thymocyte globulin on graft-versus-host disease risk among HLA-matched related donors undergoing allogeneic hematopoietic cell transplantation for aplastic anemia

Daniel Olivieri, Ted Gooley, Shivaprasad Manjappa et al. Nov 03, 2025 pp. 6005-6005 10.1182/blood-2025-6005

Abstract Introduction: Severe aplastic anemia (SAA) is a life-threatening bone marrow failure disorder curable with allogeneic hematopoietic...

Erythroid PIM1 deficiency promotes hematopoietic aging via jun/jund activation and igkc-mediated proteostasis collapse

Yuping Guan, Yazhe Zhen, Taotao Li et al. Nov 03, 2025 pp. 4950-4950 10.1182/blood-2025-4950

Abstract Anemia, the most prevalent hematological disorder in the elderly, commonly presents with accelerated aging phenotypes in severe cas...

ICE therapy for primary and secondary central nervous system involvement of lymphomas

Nasrin Dahamsha, Alon Rozental, Pia Raanani et al. Nov 03, 2025 pp. 3701-3701 10.1182/blood-2025-3701

Abstract Central nervous system (CNS) lymphomas, including primary CNS lymphoma (PCNSL) and secondary CNS lymphoma (sCNSL), are aggressive a...

Anti-CD19 CAR-T cells for Mantle Cell Lymphoma with central nervous system involvement: A study of the french descart registry.

Stephanie Guidez, Marie-Thérèse Rubio, Roberta Di Blasi et al. Nov 03, 2025 pp. 3598-3598 10.1182/blood-2025-3598

Abstract Background Chimeric antigen receptor (CAR) T-cell therapy has recently shown promise in treating diffuse large...

Targeted hyperactivation of oncogenic STAT5-signaling in acute lymphoblastic leukemia

Kohei Kume, Zhangliang Cheng, Jian Xin Lin et al. Nov 03, 2025 pp. 433-433 10.1182/blood-2025-433

Abstract Background and Significance: Oncogenic tyrosine kinases activate STAT5a and STAT5b to promote survival and proliferation in acute l...

Polatuzumab vedotin combined with orelabrutinib and rituximab (PRO Regimen) as frontline therapy in elderly and frail patients with diffuse large B-cell lymphoma (DLBCL): Results from A phase II study

Wenyu Shi, Huayuan Zhu, Jianyong Li et al. Nov 03, 2025 pp. 5477-5477 10.1182/blood-2025-5477

Abstract Title: Polatuzumab Vedotin Combined with Orelabrutinib and Rituximab (PRO Regimen) as Frontline Therapy in Elderly and Frail Patien...

Inhibition of prolyl-tRNA synthetase sensitizes acute myeloid leukemia to venetoclax through bmf-mediated apoptosis

Yuri Okazoe-Hirakawa, keiji Kurata, Hidetomo Takakura et al. Nov 03, 2025 pp. 1454-1454 10.1182/blood-2025-1454

Abstract Acute myeloid leukemia (AML) is an aggressive hematologic malignancy associated with a poor prognosis. Despite recent advances in t...

Generation of faithful autochthonous mouse models of Mantle Cell Lymphoma

Nicolas Moenig, Paul Broeckelmann, Claus Moritz Graef et al. Nov 03, 2025 pp. 1757-1757 10.1182/blood-2025-1757

Abstract Introduction: MantleCell Lymphoma (MCL) is characterized by the translocation t(11;14) resulting in overexpression of Cyclin D1. Ot...

Estimating incidence and prevalence of polycythemia vera and associated eligibility for cytoreductive therapies in major US health plans

Paul Walden, Craig Zimmerman, Noemi Hummel et al. Nov 03, 2025 pp. 8202-8202 10.1182/blood-2025-8202

Abstract Introduction: Polycythemia vera (PV) is a rare myeloproliferative neoplasm (MPN) characterized by elevated red blood cell productio...

Clinical impact of FLT3 microclones on outcomes in patients with newly diagnosed FLT3-ITD negative AML: A subanalysis from the pethema quiwi trial

Claudia Sargas, Augustin Boudry, Pilar Lloret Madrid et al. Nov 03, 2025 pp. 1719-1719 10.1182/blood-2025-1719

Abstract Background: FLT3-ITD negative acute myeloid leukemia (AML) remains challenging to treat, with limited targeted therapeutic options...

CD44v6 promotes anti-apoptotic phenotypes in AML via an SPP1-mediated autocrine activation of the MAPK-dusp pathway

Jia Wu, Xiaoya Cai, Ying Liu et al. Nov 03, 2025 pp. 7019-7019 10.1182/blood-2025-7019

Abstract Background:Acute myeloid leukemia (AML) is a highly heterogeneous hematological malignancy originating from the bone marrow. Comple...

Myelodysplastic/myeloproliferative overlap neoplasms: Clinicopathological features, treatment strategies, and outcomes — a UK multicentre cohort Study

Ahmad Alabdulkarim, Michael Luong, Yu-Hung Wang et al. Nov 03, 2025 pp. 7365-7365 10.1182/blood-2025-7365

Abstract Background: Myelodysplastic/Myeloproliferative overlap neoplasms (MDS/MPN) are rare, clonal malignancies displaying clinicopatholog...

A prospecitive, multicenter study of chidamide in adult patients with refractory primary immune thrombocytopenia

Lu Sun, Juan Wang, Yan Wang et al. Nov 03, 2025 pp. 3043-3043 10.1182/blood-2025-3043

Abstract Background: Primary immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder. Our preclinical data revealed that c...

Cutaneous and peripheral T-cell lymphomas in the u.S. population: A 25-year national review of epidemiological burden and racialdisparities

Nayanika Tummala, Sandhya Rani Reddy, Arshiya Shabnam et al. Nov 03, 2025 pp. 7159-7159 10.1182/blood-2025-7159

Abstract Cutaneous and Peripheral T-cell Lymphomas in the U.S. population: A 25-Year National Review of Epidemiological Burden and Racial Di...

Lipoprotein(a) plasma levels and coagulation biomarkers: Results from a comprehensive laboratory assessment in an angiographically-controlled cardiovascular cohort.

Nicola Osti, Gerardo Musuraca, Marianna Spizzo et al. Nov 03, 2025 pp. 4874-4874 10.1182/blood-2025-4874

Abstract Background: lipoprotein(a) [Lp(a)] is an established risk factor for cardiovascular disease. Among the molecular mechanisms underly...

Transfusion independence, hematological improvement and associated safety outcomes with bexmarilimab and azacitidine in HR-MDS: Results of the bexmab Phase 1/2 study

Mika Kontro, Anthony Selwyn Stein, Johanna Rimpiläinen et al. Nov 03, 2025 pp. 5627-5627 10.1182/blood-2025-5627

Abstract Introduction Hypomethylating (HMA) agents, including azacitidine, are standard frontline agents for HR MDS pati...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page